In recent years, research on mesenchymal stem cells (MSCs) for treating Discogenic Low Back Pain (DLBP) has been steadily increasing, yet there remains a lack of Meta-analysis focusing specifically on autologous MSCs (AMSCs) for this condition. This study comprehensively analyzes all published research on AMSCs in the treatment of DLBP and summarizes the evidence-based medical findings regarding the efficacy of this regenerative therapy for DLBP.
Methods
A comprehensive literature search was conducted across PubMed, Embase, Web of Science, and Ovid databases for articles published from database inception through April 2025. Following rigorous screening of all identified studies investigating AMSCs for DLBP treatment and performing a meta-analysis to evaluate the collective evidence.
Results
Four studies were included in our analysis, all of which were prospective single-arm trials (PSATs). The meta-analysis demonstrated significant reductions in Visual Analog Scale (VAS) and Oswestry Disability Index (ODI). Pain score decreased by >30% and >50% from baseline, with incidence rates of 52.20%, 66.00%, 67.90%, and 76.80% for >30% reduction, and 34.21%, 50.74%, 69.32%, and 67.74% for >50% reduction at these respective time points. Subgroup analysis revealed no statistically significant difference in the incidence of >30% or >50% pain score reduction between the AMSCs + hyaluronic acid (HA) combination group and AMSCs monotherapy group at equivalent follow-up intervals.
Conclusion
Intradiscal injection of AMSCs demonstrates both safety and clinical efficacy in the treatment of DLBP. The 6-month follow-up represents a clinically meaningful timepoint for evaluating the therapeutic effects of AMSCs. No significant differences were observed between AMSCs combined with HA and AMSCs monotherapy in terms of clinical outcomes.
MaherCUnderwoodMBuchbinderR. Non-specific low back pain. Lancet2017; 389: 736–747.
2.
ChouR. Low back pain. Ann Intern Med2021; 174: ITC113–ITC128.
3.
BalaguéFMannionAFPelliséF, et al.Non-specific low back pain. Lancet2012; 379: 482–491.
4.
de SchepperEIDamenJvan MeursJB, et al.The association between lumbar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. Spine (Phila Pa 1976)2010; 35: 531–536.
5.
CheungKMKarppinenJChanD, et al.Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. Spine (Phila Pa 1976)2009; 34: 934–940.
6.
SchwarzerACAprillCNDerbyR, et al.The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. Spine (Phila Pa 1976)1995; 20: 1878–1883.
7.
ManchikantiLSinghVPampatiV, et al.Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician2001; 4: 308–316.
8.
DePalmaMJKetchumJMSaulloT. What is the source of chronic low back pain and does age play a role. Pain Med2011; 12: 224–233.
9.
OhtoriSInoueGMiyagiM, et al.Pathomechanisms of discogenic low back pain in humans and animal models. Spine J2015; 15: 1347–1355.
10.
Mohd IsaILTeohSLMohd NorNH, et al.Discogenic low back pain: anatomy, pathophysiology and treatments of intervertebral disc degeneration. Int J Mol Sci2022; 24: 208.
11.
FengFXuQYanF, et al.Comparison of 7 surgical interventions for lumbar disc herniation: a network meta-analysis. Pain Physician2017; 20: E863–E871.
12.
WuPHKimHSJangIT. Intervertebral disc diseases PART 2: a review of the current diagnostic and treatment strategies for intervertebral disc disease. Int J Mol Sci2020; 21: 2135.
13.
RichardsonSMKalamegamGPushparajPN, et al.Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods2016; 99: 69–80.
14.
Fernández-FrancosSEiroNCostaLA, et al.Mesenchymal stem cells as a cornerstone in a galaxy of intercellular signals: basis for a new era of medicine. Int J Mol Sci2021; 22: 3576.
15.
HaDHKimHKLeeJ, et al.Mesenchymal stem/stromal cell-derived exosomes for immunomodulatory therapeutics and skin regeneration. Cells2020; 9: 1157.
16.
ShiJZhaoYCNiuZF, et al.Mesenchymal stem cell-derived small extracellular vesicles in the treatment of human diseases: progress and prospect. World J Stem Cells2021; 13: 49–63.
17.
SunSJWeiRLiF, et al.Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair. Stem Cell Rep2021; 16: 1662–1673.
18.
MatteiVDelle MonacheS. Mesenchymal stem cells and their role in neurodegenerative diseases. Cells2024; 13: 779.
19.
ChenXZhengJYinL, et al.Transplantation of three mesenchymal stem cells for knee osteoarthritis, which cell and type are more beneficial? A systematic review and network meta-analysis. J Orthop Surg Res2024; 19: 366.
20.
ZhangWWangDLiH, et al.Mesenchymal stem cells can improve discogenic pain in patients with intervertebral disc degeneration: a systematic review and meta-analysis. Front Bioeng Biotechnol2023; 11: 1155357.
21.
LohanPTreacyOGriffinMD, et al.Anti-Donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning. Front Immunol2017; 8: 1626.
22.
LiberatiAAltmanDGTetzlaffJ, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J2009; 339: b2700.
23.
MaKZhuangZGWangL, et al.The Chinese association for the study of pain (CASP): consensus on the assessment and management of chronic nonspecific low back pain. Pain Res Manag2019; 2019: 8957847.
24.
FischgrundJSMontgomeryDM. Diagnosis and treatment of discogenic low back pain. Orthop Rev1993; 22: 311–318.
25.
OsteloRWDeyoRAStratfordP, et al.Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976)2008; 33: 90–94.
26.
FarrarJTYoungJPJrLaMoreauxL, et al.Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain2001; 94: 149–158.
27.
OrozcoLSolerRMoreraC, et al.Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation2011; 92: 822–828.
28.
KumarHHaDHLeeEJ, et al.Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther2017; 8: 262.
29.
BatesDVivianDFreitagJ, et al.Low-dose mesenchymal stem cell therapy for discogenic pain: safety and efficacy results from a 1-year feasibility study. Future Sci OA2022; 8: FSO794.
30.
VadalàGSowaGHubertM, et al.Mesenchymal stem cells injection in degenerated intervertebral disc: cell leakage may induce osteophyte formation. J Tissue Eng Regen Med2012; 6: 348–355.
31.
LiYYDiaoHJChikTK, et al.Delivering mesenchymal stem cells in collagen microsphere carriers to rabbit degenerative disc: reduced risk of osteophyte formation. Tissue Eng Part A2014; 20: 1379–1391.
32.
FangCZhangWChenL, et al.The correlation between the high-intensity zone on a T2-weighted MRI and positive outcomes of discography: a meta-analysis. J Orthop Surg Res2017; 12: 26.
33.
YangLLiWYangY, et al.The correlation between the lumbar disc MRI high-intensity zone and discogenic low back pain: a systematic review and meta-analysis. J Orthop Surg Res2023; 18: 758.
34.
LeeDHParkKSShinHE, et al.Safety and feasibility of intradiscal administration of matrilin-3-primed adipose-derived mesenchymal stromal cell spheroids for chronic discogenic low back pain: phase 1 clinical trial. Int J Mol Sci2023; 24: 16827.
35.
UfonduWRobinsonCLHussainN, et al.Intradiscal autologous biologics for the treatment of chronic discogenic low back pain. Curr Pain Headache Rep2024; 28: 1079–1095.
36.
CentenoCMarkleJDodsonE, et al.Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. J Transl Med2017; 15: 197.
37.
LewandrowskiKUDowlingAVeraJC, et al.Pain relief after allogenic stem cell disc therapy. Pain Physician2023; 26: 197–206.
38.
CofanoFBoidoMMonticelliM, et al.Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int J Mol Sci2019; 20: 2698.
OhtaYHamaguchiAOotakiM, et al.Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury. Cytotherapy2017; 19: 839–848.
41.
MinonzioGCorazzaMMariottaL, et al.Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. Cryobiology2014; 69: 211–216.
42.
RossiFPeraleGPapaS, et al.Current options for drug delivery to the spinal cord. Expert Opin Drug Deliv2013; 10: 385–396.
43.
InoueMIsaIOritaS, et al.An injectable hyaluronic acid hydrogel promotes intervertebral disc repair in a rabbit model. Spine (Phila Pa 1976)2021; 46: E810–E816.
44.
IsaILSrivastavaATiernanD, et al.Hyaluronic acid based hydrogels attenuate inflammatory receptors and neurotrophins in interleukin-1β induced inflammation model of nucleus Pulposus cells. Biomacromolecules2015; 16: 1714–1725.
45.
ZhangFWangSGaoM, et al.Hyaluronic acid ameliorates intervertebral disc degeneration via promoting mitophagy activation. Front Bioeng Biotechnol2022; 10: 1057429.
